Hemispherian is a Norway-based preclinical pharmaceutical company. We are advancing a new class of cancer therapeutics that are specifically designed to treat some of the most aggressive forms of cancer. These drugs are expected to be exceptionally well tolerated resulting in few, if any, side effects. The drugs target the DNA damage response pathway by acting on an entirely new Mechanism of Action that is present uniquely in cancer cells
#glioblastoma #GBM #oncology